Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

EPIX

Essa Pharma Inc

Nov 21 • 04:00PM ET

1.76

Dollar change +0.03
Percentage change 1.73	%

Healthcare • Biotechnology • Canada • NASD

Peers: JNJ MRK PFE BMY LLY GSK NVS AZN ABBV SNY

| Held by: AVSC

Index	-	P/E	-	EPS (ttm)	-0.63	Insider Own	2.22%	Shs Outstand	44.10M	Perf Week	0.00%
Market Cap	78.09M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	-88.89%	Shs Float	43.38M	Perf Month	-67.23%
Income	-27.67M	PEG	-	EPS next Q	-0.19	Inst Own	98.86%	Short Float	2.65%	Perf Quarter	-66.22%
Sales	0.00M	P/S	-	EPS this Y	-13.00%	Inst Trans	72.35%	Short Ratio	1.43	Perf Half Y	-72.06%
Book/sh	2.90	P/B	0.61	EPS next Y	15.34%	ROA	-19.33%	Short Interest	1.15M	Perf Year	-69.71%
Cash/sh	2.95	P/C	0.60	EPS next 5Y	-	ROE	-19.83%	52W Range	1.40 - 11.67	Perf YTD	-73.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	25.04%	ROI	-21.43%	52W High	-84.92%	Beta	1.72
Dividend TTM	-	Quick Ratio	36.95	Sales past 5Y	0.00%	Gross Margin	-	52W Low	25.71%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	36.95	EPS Y/Y TTM	-0.58%	Oper. Margin	0.00%	RSI (14)	24.56	Volatility	5.71% 7.75%
Employees	50	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	11.39
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	1.51%	Payout	-	Rel Volume	0.34	Prev Close	1.73
Sales Surprise	-	EPS Surprise	34.96%	Sales Q/Q	-	Earnings	Aug 05 BMO	Avg Volume	803.04K	Price	1.76
SMA20	-33.31%	SMA50	-62.80%	SMA200	-71.35%	Trades		Volume	273,142	Change	1.73%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-24	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $2
Nov-04-24	Downgrade	Oppenheimer	Outperform → Perform
Nov-04-24	Downgrade	Jefferies	Buy → Hold
Jun-26-23	Resumed	Oppenheimer	Outperform	$17
Mar-04-21	Initiated	Piper Sandler	Overweight	$50
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$10 → $17
Nov-02-20	Initiated	Jefferies	Buy	$17
Oct-25-19	Initiated	Oppenheimer	Outperform	$8

Nov-04-24 08:14AM	ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials (Investing.com) +16.43%
Nov-01-24 08:14AM	ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment (Clinical Trials Arena) -73.08%
Oct-31-24 08:57PM	ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Sep-14-24 09:53PM	ESSA Pharma Inc. (EPIX): Wall Street Analysts Recommend This Canadian Stock Right Now (Insider Monkey)
Sep-13-24 05:19PM	ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress (PR Newswire)
04:05PM	Loading…
Sep-11-24 04:05PM	ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire) +8.95%
Aug-05-24 07:03AM	ESSA Pharma: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 (PR Newswire)
Jul-08-24 04:05PM	ESSA Pharma to Present at the JonesHealthcare Seaside Summit (PR Newswire)
May-30-24 08:00AM	ESSA Pharma to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-20-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +9.47%
May-14-24 01:54PM	EPIX Stock Earnings: ESSA Pharma Misses EPS for Q2 2024 (InvestorPlace)
07:04AM	ESSA Pharma: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 (PR Newswire)
Apr-09-24 08:00AM	ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire) -7.20%
08:13PM	Loading…
Mar-07-24 08:13PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire) +5.62%
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey)
Feb-14-24 04:35AM	ESSA Pharma Inc (EPIX) Reports Q1 Fiscal 2024 Financial Results (GuruFocus.com)
Feb-13-24 07:25AM	ESSA Pharma: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 (PR Newswire)
Feb-07-24 08:47PM	ESSA Pharma Inc Executive Peter Virsik Sells 72,782 Shares (GuruFocus.com)
Feb-06-24 08:00AM	ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire) +5.29%
Jan-25-24 10:00AM	ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium (PR Newswire) -22.64%
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey) +9.34%
Dec-12-23 12:03PM	EPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023 (InvestorPlace)
09:12AM	ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ... (GuruFocus.com)
07:20AM	ESSA Pharma: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023 (PR Newswire)
Nov-23-23 11:05AM	Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 Shares (GuruFocus.com)
Nov-21-23 08:00AM	ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +7.59%
08:00AM	Loading…
Nov-08-23 08:00AM	ESSA Pharma to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-06-23 05:51PM	ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement (PR Newswire) -13.17%
Oct-30-23 10:59AM	EPIX: Dose Escalation Data for Combination of Masofaniten (EPI-7386) and Enzalutamide Presented at PCF Retreat (Zacks) +8.82%
Oct-26-23 05:41PM	ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire) +10.09%
Oct-21-23 09:00AM	ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress (PR Newswire)
Sep-18-23 07:00AM	ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Aug-31-23 07:00AM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (PR Newswire)
Aug-14-23 08:43AM	EPIX: Phase 2 Trial of EPI-7386 in Combination with Enzalutamide to Initiate in Calendar 3Q23 (Zacks) +6.57%
Aug-08-23 07:17AM	ESSA Pharma: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 (PR Newswire)
Jun-06-23 07:00AM	ESSA Pharma Appoints Lauren Merendino to its Board of Directors (PR Newswire)
Jun-01-23 07:00AM	ESSA Pharma to Present at 2023 Jefferies Healthcare Conference (PR Newswire)
May-24-23 11:04AM	We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely (Simply Wall St.)
May-18-23 06:25AM	EPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research)
May-11-23 07:00AM	ESSA Pharma to Present at JMP Securities Life Sciences Conference (PR Newswire) +6.43%
May-09-23 07:19AM	ESSA Pharma: Fiscal Q2 Earnings Snapshot (AP Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 (PR Newswire)
Apr-18-23 07:00AM	ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-12-23 07:00AM	ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer (PR Newswire) -5.82%
Mar-08-23 07:00AM	ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-07-23 05:19AM	ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Feb-23-23 05:43AM	EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research)
Feb-13-23 05:00PM	ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (PR Newswire) +5.15% +10.13%
Feb-07-23 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 (PR Newswire)
Feb-02-23 04:01PM	ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference (PR Newswire) +6.52%
Jan-25-23 05:39AM	A Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX) (Simply Wall St.) -5.50%
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research)
Dec-21-22 05:07PM	Examining Penny Stocks with Technical Analysis (Investopedia) -5.91%
Dec-19-22 08:11AM	EPIX: Advancing Multiple Clinical Trials in 2023 (Zacks Small Cap Research)
Dec-15-22 08:30AM	We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate (Simply Wall St.) -5.02%
Dec-13-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022 (PR Newswire)
Nov-14-22 09:25AM	EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research) -7.90%
Nov-10-22 07:00AM	ESSA Pharma to Participate in Two Upcoming Investor Conferences (PR Newswire) +7.17%
Oct-31-22 11:13AM	ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials (Benzinga) -18.37%
08:58AM	J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment (MarketWatch)
07:00AM	ESSA Provides an Update on its Clinical Collaboration with Janssen (PR Newswire)
Oct-26-22 04:01PM	ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium (PR Newswire) +180.23% -9.75%
07:00AM	Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
Sep-13-22 07:00AM	ESSA Pharma Appoints Philip Kantoff to its Board of Directors (PR Newswire)
Aug-10-22 06:40AM	EPIX: Multiple Ongoing Studies of EPI-7386 (Zacks Small Cap Research)
Aug-04-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 (PR Newswire)
Jul-11-22 07:23AM	EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386 (Zacks Small Cap Research)
Jun-30-22 06:21PM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (PR Newswire) -9.48% -10.48%
Jun-28-22 06:29AM	ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer (Benzinga) -9.55%
Jun-27-22 04:01PM	ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development (PR Newswire)
Jun-02-22 07:00AM	ESSA Pharma to Present at 2022 Jefferies Healthcare Conference (PR Newswire) +5.64%
May-27-22 08:12AM	EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22 (Zacks Small Cap Research)
May-10-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 (PR Newswire) +7.68%
Apr-26-22 04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-25-22 10:20AM	EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR (Zacks Small Cap Research)
Apr-08-22 01:00PM	ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders (PR Newswire)
Mar-10-22 04:05PM	ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference (PR Newswire)
Mar-09-22 11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire)
Mar-08-22 04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Feb-04-22 05:16AM	EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research) +5.13%
Feb-03-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 (PR Newswire)
Jan-19-22 07:00AM	ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) -6.80%
Dec-11-21 05:38AM	Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Nov-22-21 09:20AM	EPIX: Combination Studies Set to Initiate (Zacks Small Cap Research)
Nov-18-21 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021 (PR Newswire)
Nov-08-21 07:00AM	ESSA Pharma to Participate in Three Upcoming Investor Conferences (PR Newswire)
Oct-28-21 04:05PM	ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
Oct-19-21 01:21PM	Hedge Funds Are Done Buying ESSA Pharma Inc. (EPIX) (Insider Monkey) +5.13%
Oct-07-21 10:25AM	ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact (Benzinga) +5.03%
09:00AM	ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386 (PR Newswire)
06:30AM	Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration (PR Newswire)

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH GROWTH N V	10% Owner	Nov 01 '24	Sale	1.53	7,879,583	12,018,409	0	Nov 05 12:06 PM
Virsik Peter	Chief Operating Officer	Oct 07 '24	Sale	6.03	694	4,185	7,776	Oct 07 03:00 PM
Virsik Peter	Chief Operating Officer	Sep 09 '24	Sale	6.00	694	4,164	8,470	Sep 09 02:03 PM
Virsik Peter	Chief Operating Officer	Sep 03 '24	Sale	6.03	2,082	12,554	9,164	Sep 03 06:57 PM
Virsik Peter	Officer	Sep 03 '24	Proposed Sale	5.59	4,164	23,277		Sep 03 04:17 PM
Virsik Peter	Chief Operating Officer	May 06 '24	Sale	6.95	694	4,823	11,246	May 06 05:17 PM
Glickman Richard M	Director	Apr 24 '24	Option Exercise	4.90	3,750	18,375	43,240	Apr 25 10:35 AM
Virsik Peter	Chief Operating Officer	Apr 05 '24	Sale	7.94	694	5,510	11,940	Apr 05 06:16 PM
Virsik Peter	Chief Operating Officer	Mar 05 '24	Sale	8.98	694	6,232	12,634	Mar 05 06:50 PM
Virsik Peter	Chief Operating Officer	Feb 06 '24	Option Exercise	3.23	72,782	235,086	86,110	Feb 07 11:29 AM
Virsik Peter	Chief Operating Officer	Feb 06 '24	Sale	10.29	72,782	748,927	13,328	Feb 07 11:29 AM
Virsik Peter	Chief Operating Officer	Feb 05 '24	Option Exercise	3.23	500	1,615	13,828	Feb 06 08:27 AM
Virsik Peter	Chief Operating Officer	Feb 05 '24	Sale	9.58	1,194	11,440	13,328	Feb 06 08:27 AM
Virsik Peter	Chief Operating Officer	Jan 16 '24	Option Exercise	3.23	1,718	5,549	15,740	Jan 17 08:57 PM
Virsik Peter	Chief Operating Officer	Jan 16 '24	Sale	10.01	1,718	17,197	14,022	Jan 17 08:57 PM
Virsik Peter	Chief Operating Officer	Jan 05 '24	Sale	6.11	699	4,271	14,022	Jan 08 08:06 PM
Parkinson David Ross	Chief Executive Officer	Dec 14 '23	Buy	2.30	9,223	21,213	65,675	Dec 18 09:57 PM

Dollar change 0.00
Percentage change 0.00	%

BDTX Black Diamond Therapeutics Inc daily Stock Chart

Peers: BPMC FATE IGMS ALLO ADAP CARA XFOR CRBP

| Held by: VTI IWM VXF IWO VTWO FESM IWN IWC DFAC VFMO

Index	RUT	P/E	-	EPS (ttm)	-1.36	Insider Own	24.20%	Shs Outstand	51.65M	Perf Week	-14.74%
Market Cap	137.50M	Forward P/E	-	EPS next Y	-1.22	Insider Trans	-1.59%	Shs Float	42.89M	Perf Month	-20.59%
Income	-73.10M	PEG	-	EPS next Q	-0.31	Inst Own	75.29%	Short Float	14.75%	Perf Quarter	-62.38%
Sales	0.00M	P/S	-	EPS this Y	30.85%	Inst Trans	13.58%	Short Ratio	5.26	Perf Half Y	-48.73%
Book/sh	1.72	P/B	1.41	EPS next Y	5.93%	ROA	-47.12%	Short Interest	6.33M	Perf Year	8.97%
Cash/sh	1.99	P/C	1.22	EPS next 5Y	-	ROE	-63.09%	52W Range	2.14 - 7.66	Perf YTD	-13.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-49.79%	ROI	-62.43%	52W High	-68.28%	Beta	2.49
Dividend TTM	-	Quick Ratio	5.55	Sales past 5Y	0.00%	Gross Margin	-	52W Low	13.29%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	5.55	EPS Y/Y TTM	35.89%	Oper. Margin	0.00%	RSI (14)	29.57	Volatility	7.62% 7.18%
Employees	54	Debt/Eq	0.24	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	14.50
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	39.04%	Payout	-	Rel Volume	0.49	Prev Close	2.43
Sales Surprise	-	EPS Surprise	24.99%	Sales Q/Q	-	Earnings	Nov 05 BMO	Avg Volume	1.20M	Price	2.43
SMA20	-16.77%	SMA50	-31.70%	SMA200	-49.97%	Trades		Volume	584,822	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-31-24	Initiated	Raymond James	Outperform	$20
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy	$2 → $10
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$11
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform	$10
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold	$10
Jan-07-21	Initiated	Wedbush	Outperform	$45
Nov-24-20	Initiated	Berenberg	Buy	$58
May-04-20	Initiated	H.C. Wainwright	Buy	$53
Feb-24-20	Initiated	JP Morgan	Overweight	$42
Feb-24-20	Initiated	Jefferies	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	Canaccord Genuity	Buy	$50

Show Previous Ratings

Nov-05-24 09:00AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance) +8.70%
08:00AM	Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.47%
Oct-07-24 04:01PM	Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway (GlobeNewswire)
Sep-23-24 11:43AM	Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug (Benzinga) -5.46%
07:00AM	Loading…
07:00AM	Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations (GlobeNewswire)
Sep-22-24 10:00AM	Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC (GlobeNewswire)
Sep-14-24 03:30AM	Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-08-24 04:05PM	Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors (GlobeNewswire) +6.25%
12:00PM	All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy (Zacks)
Aug-06-24 01:53PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024 (InvestorPlace) -5.57%
07:37AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-29-24 08:28PM	Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
10:00AM	Loading…
Jun-01-24 10:00AM	Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-29-24 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 08:23AM	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating (MT Newswires)
May-10-24 08:46AM	Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings? (Zacks) -9.48%
May-09-24 01:54PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:28AM	Black Diamond: Q1 Earnings Snapshot (Associated Press Finance)
Apr-29-24 08:50AM	Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Apr-25-24 09:55AM	Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect? (Zacks)
Apr-24-24 04:05PM	Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-15-24 12:00PM	Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-11-24 08:00AM	Black Diamond Therapeutics Announces Changes to Board of Directors (GlobeNewswire) +11.85%
Apr-08-24 09:55AM	Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know (Zacks) +5.73%
Apr-07-24 06:00PM	Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Apr-03-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.71%
Mar-22-24 09:55AM	How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93% (Zacks) +6.10%
Mar-14-24 05:31AM	Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ... (GuruFocus.com) +8.35%
Mar-12-24 08:32AM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance) -5.50%
08:00AM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024 (GlobeNewswire)
Feb-28-24 08:00AM	Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-04-24 08:00AM	Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones (GlobeNewswire)
Dec-13-23 07:00AM	Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM (GlobeNewswire) -9.03%
Nov-07-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-23 08:07AM	Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update (GuruFocus.com)
07:48AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance)
07:45AM	Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-20-23 12:54PM	Hedge Fund and Insider Trading News: John Paulson, Sanjay Shah, Doug Kass, Point72 Asset Management, Balyasny Asset Management, Black Diamond Therapeutics, Inc. (BDTX), Delta Air Lines, Inc. (DAL), and More (Insider Monkey)
Oct-14-23 12:30PM	Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535 (GlobeNewswire)
Oct-04-23 12:14PM	Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -5.56%
Sep-18-23 12:34PM	Co-founder of cancer biotech Black Diamond replaced as CEO (American City Business Journals)
07:00AM	Black Diamond Therapeutics Announces CEO Transition (GlobeNewswire)
Sep-11-23 08:00AM	Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-05-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-11-23 07:35AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-25-23 07:43AM	Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jul-16-23 10:05AM	TipRanks Perfect 10 List: These Monster Growth Stocks Could Reach New Highs (TipRanks)
Jun-29-23 08:57PM	Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -12.22%
05:48PM	Why Shares of Black Diamond Therapeutics Skyrocketed This Week (Motley Fool)
Jun-28-23 04:23PM	Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -7.28%
07:15AM	Institutions profited after Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) market cap rose US$152m last week but private equity firms profited the most (Simply Wall St.)
Jun-27-23 07:00AM	Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families (GlobeNewswire) +235.87%
Jun-13-23 08:00AM	Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer (GlobeNewswire) +5.34%
Jun-02-23 08:00AM	Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +8.84%
May-18-23 10:17AM	Black Diamond Therapeutics Insider Ups Holding By 82% During Year \ (Simply Wall St.) -6.36%
May-09-23 07:46AM	Black Diamond: Q1 Earnings Snapshot (AP Finance) -5.21%
07:30AM	Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-18-23 08:00AM	Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days (GlobeNewswire)
Apr-17-23 04:01PM	Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:52AM	Black Diamond: Q4 Earnings Snapshot (AP Finance) -13.69%
07:30AM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-27-23 08:00AM	Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire) -9.31%
Feb-15-23 05:46AM	Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth? (Simply Wall St.) -7.72%
Jan-19-23 05:41AM	private equity firms who own 40% along with institutions invested in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw increase in their holdings value last week (Simply Wall St.)
Jan-05-23 08:00AM	Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-22 08:00AM	Black Diamond Therapeutics Announces Changes to Board of Directors (GlobeNewswire)
Dec-12-22 08:00AM	Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company (GlobeNewswire)
Dec-09-22 09:35AM	Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) (Zacks)
09:04AM	Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) recent US$17m market cap decline means a loss of US$21k for insiders who bought this year (Simply Wall St.)
Nov-09-22 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.70%
Nov-08-22 08:00AM	Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-26-22 08:00AM	Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-22 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.51%
Aug-28-22 09:41AM	We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Aug-09-22 08:00AM	Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-22 08:00AM	Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-01-22 08:55AM	Could The Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jul-02-22 08:29AM	CFO, Principal Financial Officer and Chief Business Officer Fang Ni Just Bought 57% More Shares In Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) (Simply Wall St.)
Jun-06-22 08:00AM	Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
Jun-01-22 07:00AM	Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
May-17-22 07:00AM	Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +5.91%
May-12-22 04:30PM	Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine (GlobeNewswire)
May-11-22 04:30PM	Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.88%
Apr-28-22 12:52PM	Two years after massive IPO, cancer startup makes workforce cuts (American City Business Journals)
Apr-25-22 09:00AM	Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment (GlobeNewswire)
Apr-18-22 07:00AM	Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer (GlobeNewswire)
Apr-07-22 04:30PM	Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire) +14.14%
07:00AM	Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors (GlobeNewswire)
Mar-17-22 05:00PM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-02-22 08:00AM	Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-22-22 08:00AM	Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer (GlobeNewswire) -5.65%
Feb-16-22 05:28AM	Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely? (Simply Wall St.)

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Versant Venture Capital VI, L.	10% Owner	Aug 28 '24	Sale	6.32	221,600	1,400,556	3,726,341	Aug 30 04:16 PM
David Epstein	Former Employer	Jul 31 '24	Proposed Sale	6.20	50,000	310,000		Jul 31 04:18 PM
David Epstein	Former Employee	Jul 26 '24	Proposed Sale	6.20	50,000	310,000		Jul 26 05:54 PM

EPIX

Essa Pharma Inc

BDTX

Black Diamond Therapeutics Inc

Upgrade your FINVIZ experience